Reuters logo
BRIEF-Lilly and Astrazeneca receive FDA fast track designation for AZD3293
August 22, 2016 / 10:21 AM / a year ago

BRIEF-Lilly and Astrazeneca receive FDA fast track designation for AZD3293

Aug 22 (Reuters) - Eli Lilly And Co :

* Lilly and Astrazeneca receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

* Also announced planned initiation of a second phase 3 trial for azd3293 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below